• GIC in the US$27 billion sale of Refinitiv by a consortium (consisting of Blackstone, an affiliate of GIC, Canada Pension Plan Investment Board and Thomson Reuters) to London Stock Exchange Group plc, representing the largest PE exit in 2019, according to Bloomberg. 
    • Cinépolis, a Mexico-based cinema exhibitor, on its proposed acquisition of Moviehouse & Eatery, an upscale dine-in movie theatre circuit in Texas.
    • Kinross Gold Corporation in its acquisition of two Brazilian hydroelectric power plants through its wholly-owned subsidiary Kinross Brasil Mineraçao.
    • Cinemex Holdings USA, Inc. in its acquisition of Cobb Theaters, a modern, premium circuit of 28 theater locations across the southeastern United States.
    • Laguna Dairy, S.A. de C.V., a multinational fresh fluid dairy processor based in Mexico, in the sale of Borden to ACON Investments, LLC via an equity recapitalization.
    • Grupo Mexico SAB de CV’s transportation business unit, GMéxico Transportes S.A. de C.V, in its acquisition of the Florida East Coast Railway Holdings Corp, a freight transportation business headquartered in Coral Gables, Florida.
    • Affiliates of Bregal Partners in connection with its investment in American Seafoods Group, LLC, the largest harvester of wild-caught fish for human consumption in the United States, as part of a broader deleveraging recapitalization of American Seafoods Group, LLC.
    • GIC, the sovereign wealth fund of Singapore, in its US$350 million investment in Kronos Inc., a company focused on delivering workforce management solutions in the cloud, as part of a broader recapitalization of Kronos.
    • Court Square Capital Partners in a number of its transactions, including the US$1.12 billion sale of the Harvard Drug Group to Cardinal Health Inc., and various portfolio company acquisitions.
    • Compañía Perforadora de México S.A.P.I. de C.V. (PEMSA), a wholly-owned subsidiary of Grupo México S.A.B. de C.V., in five acquisitions of jackup rigs and drilling platforms for a total value of approximately US$1 billion for use in oil exploration and drilling in the Gulf of Mexico.
    • Celgene Corporation on its 2015 acquisition of Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery for US$100 million at closing and an additional earnout of US$385 million.
    • Switzerland-based Ferring Pharmaceuticals on its 2014 acquisition of DDAVP® (desmopressin acetate) from Sanofi.
    • R-Pharm US in its acquisition of the breast cancer drug Ixempra (ixabepilone) from Bristol-Myers Squibb.
    • Tekla Capital Management LLC and its affiliates in a broad range of investments in private biotechnology companies.
    • Sweden-based Orexo AB in its sale of the rights to the pharmaceutical product Abstral in the United States to Galena Biopharma, Inc.
    • A global asset manager in its acquisition of a leading provider of fixed-income indexing solutions.
    • CorpBanca, a Chilean bank, and its majority shareholders, in connection with a US$225 million investment from the International Finance Corporation (IFC) and certain of its affiliated funds.